

STEMCELLS INC  
Form 8-K  
February 13, 2013

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

February 12, 2013

StemCells, Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction  
of incorporation)

000-19871

(Commission  
File Number)

94-3078125

(I.R.S. Employer  
Identification No.)

7707 Gateway Blvd, Suite 140, Newark,  
California

94560

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:

510.456.4000

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



**Top of the Form**

**Item 8.01 Other Events.**

On February 12, 2013, StemCells, Inc. (the "Company") issued a press release with an update on the first patient cohort in the Company's Phase I/II clinical study in chronic spinal cord injury. The patients in the first cohort, consisting of three AIS A patients, have completed the study and twelve-month data from this cohort continued to demonstrate a favorable safety profile for the product and procedure and showed that the gains in sensory function observed in two of the three patients at the six-month assessment have persisted. The third patient remains stable. One of the patients in the cohort has converted from a complete injury assessment (AIS A) to an incomplete injury assessment (AIS B).

A copy of this press release is attached hereto as Exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

Exhibit 99.1 Press Release, dated February 12, 2013, announcing twelve-month data on the first patient cohort in the Company's clinical study of HuCNS-SC cells in spinal cord injury.

---

Edgar Filing: STEMCELLS INC - Form 8-K

**Top of the Form**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

StemCells, Inc.

*February 13, 2013*

By: */s/ Kenneth Stratton*

---

*Name: Kenneth Stratton*

*Title: General Counsel*

---

## Edgar Filing: STEMCELLS INC - Form 8-K

**Top of the Form**

### Exhibit Index

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press release dated February 12, 2013